{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:50:49Z","timestamp":1768895449555,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":318,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Glioblastoma multiforme\u00a0(GBM) is an aggressive brain tumor with poor survival rates despite current treatments. The standard of care (SOC) includes surgery, followed by radiotherapy plus concurrent and adjuvant chemotherapy with temozolomide (TMZ). This phase II trial assessed the safety and efficacy of neoadjuvant TMZ (nTMZ) before and during chemoradiotherapy in newly diagnosed GBM patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Newly diagnosed GBM patients who underwent maximal safe resection were randomized into 2 groups. One received nTMZ before standard chemoradiotherapy and adjuvant TMZ (intervention). The other received standard chemoradiotherapy followed by adjuvant TMZ (control). Primary endpoints were progression-free survival (PFS) at 6 and 12 months. Secondary endpoints included overall survival, radiological and clinical responses, and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 35 patients, 16 were in the intervention group and 19 in the control group. Median PFS was 9 months (95% CI: 3.93\u201314.06)\u00a0versus 3 months (95% confidence interval [CI]: 1.98\u20134.01) in the control and intervention groups (P = .737), with a high progression rate (73.4%) during nTMZ treatment. The 6-month PFS rates were 58% versus 25% (P\u2005=\u2005.042), and 12-month PFS rates were 26% versus 25% (P\u2005=\u2005.390) in the control and intervention groups, respectively. Patients with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) and\u00a0those with\u00a0good performance status (PS) had significantly worse PFS with nTMZ. \u00a0However, those who underwent\u00a0larger extent of resection exhibited\u00a0significantly better PFS\u00a0 with nTMZ.\u00a0Adverse events were similar between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Neoadjuvant TMZ before SOC chemoradiotherapy did not improve outcomes for newly diagnosed GBM patients and is unsuitable for those with unmethylated MGMT and good PS. However,\u00a0It may benefit patients with near or gross total resection. Further research is needed to refine GBM treatment strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdae195","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T05:30:09Z","timestamp":1731562209000},"source":"Crossref","is-referenced-by-count":3,"title":["Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results"],"prefix":"10.1093","volume":"6","author":[{"given":"Azadeh","family":"Sharifian","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Kazemian","sequence":"additional","affiliation":[{"name":"Radiation Oncology Research Center, Cancer Research Institute, IKHC,\u00a0Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Farzin","sequence":"additional","affiliation":[{"name":"Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikan","family":"Amirkhani","sequence":"additional","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borna","family":"Farazmand","sequence":"additional","affiliation":[{"name":"Radiation Oncology Research Center, Cancer Research Institute, IKHC,\u00a0Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Naderi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Iran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Khalilian","sequence":"additional","affiliation":[{"name":"Radiation Oncology Research Center, Cancer Research Institute, IKHC,\u00a0Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Pourrashidi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Sina Hospital, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazaleh","family":"Amjad","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Radiology Department, University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasra","family":"Kolahdouzan","sequence":"additional","affiliation":[{"name":"Radiation Oncology Research Center, Cancer Research Institute, IKHC,\u00a0Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-8440","authenticated-orcid":false,"given":"Romina","family":"Abyaneh","sequence":"additional","affiliation":[{"name":"Radiation Oncology Research Center, Cancer Research Institute, IKHC,\u00a0Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola Anna","family":"Jablonska","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Hospital Universitario de Navarra , Pamplona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-2019","authenticated-orcid":false,"given":"Reza","family":"Ghalehtaki","sequence":"additional","affiliation":[{"name":"Radiation Oncology Research Center, Cancer Research Institute, IKHC,\u00a0Tehran University of Medical Sciences , Tehran ,","place":["Iran"]},{"name":"Department of Radiation Oncology, Cancer Institute, IKHC, School of Medicine, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"5","key":"2024121113153681800_CIT0001","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ccr.2012.04.031","article-title":"SnapShot: glioblastoma multiforme","volume":"21","author":"Kotliarova","year":"2012","journal-title":"Cancer Cell."},{"issue":"5","key":"2024121113153681800_CIT0002","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med."},{"issue":"10","key":"2024121113153681800_CIT0003","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"23","key":"2024121113153681800_CIT0004","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA."},{"key":"2024121113153681800_CIT0005","doi-asserted-by":"crossref","first-page":"900377","DOI":"10.3389\/fneur.2022.900377","article-title":"The routine application of tumor-treating fields in the treatment of glioblastoma WHO\u00b0 IV","volume":"13","author":"Krigers","year":"2022","journal-title":"Front Neurol."},{"issue":"1","key":"2024121113153681800_CIT0006","first-page":"vdaa069","article-title":"Current usage of tumor treating fields for glioblastoma","volume":"2","author":"Lassman","year":"2020","journal-title":"Neurooncol Adv."},{"issue":"1","key":"2024121113153681800_CIT0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncol."},{"issue":"10172","key":"2024121113153681800_CIT0008","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA\u201309): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"The Lancet"},{"key":"2024121113153681800_CIT0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fonc.2020.00066","article-title":"Commentary: lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"10","author":"Das","year":"2020","journal-title":"Front Oncol."},{"issue":"7","key":"2024121113153681800_CIT0010","first-page":"2585","article-title":"Temozolomide and treatment of malignant glioma","volume":"6","author":"Friedman","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2024121113153681800_CIT0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10689-013-9607-1","article-title":"The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis","volume":"12","author":"Zhang","year":"2013","journal-title":"Fam Cancer."},{"issue":"8","key":"2024121113153681800_CIT0012","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3390\/biomedicines10082030","article-title":"MGMT promoter methylation as a prognostic factor in primary glioblastoma: a single-institution observational study","volume":"10","author":"Szylberg","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2024121113153681800_CIT0013","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11060-014-1538-7","article-title":"Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma","volume":"120","author":"Jo","year":"2014","journal-title":"J Neurooncol."},{"issue":"3","key":"2024121113153681800_CIT0014","first-page":"911","article-title":"Efficacy of temozolomide treatment in patients with high-grade glioma","volume":"29","author":"Oshiro","year":"2009","journal-title":"Anticancer Res."},{"issue":"11","key":"2024121113153681800_CIT0015","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.21564","article-title":"Salvage temozolomide for prior temozolomide responders","volume":"104","author":"Franceschi","year":"2005","journal-title":"Cancer."},{"issue":"3","key":"2024121113153681800_CIT0016","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijrobp.2016.11.006","article-title":"A phase 2 trial of neoadjuvant temozolomide followed by hypofractionated accelerated radiation therapy with concurrent and adjuvant temozolomide for patients with glioblastoma","volume":"97","author":"Shenouda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2024121113153681800_CIT0017","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1038\/s41598-020-61701-z","article-title":"Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the National Cancer Database","volume":"10","author":"Buszek","year":"2020","journal-title":"Sci Rep."},{"issue":"Suppl 6","key":"2024121113153681800_CIT0018","doi-asserted-by":"crossref","first-page":"vi219","DOI":"10.1093\/neuonc\/nox168.888","article-title":"RTHP-03. prognostic impact of timing between surgery and Radiotherapy (Rt) in patients with Glioblastoma (GBM)","volume":"19","author":"Chevli","year":"2017","journal-title":"Neuro-Oncol."},{"issue":"suppl_1","key":"2024121113153681800_CIT0019","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/jrr\/rrx103","article-title":"Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival","volume":"59","author":"Pollom","year":"2018","journal-title":"J Radiat Res."},{"issue":"4","key":"2024121113153681800_CIT0020","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/diagnostics13040795","article-title":"Timing of early postoperative MRI following primary glioblastoma surgery\u2014A retrospective study of contrast enhancements in 311 patients","volume":"13","author":"Rykkje","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2024121113153681800_CIT0021","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"issue":"3","key":"2024121113153681800_CIT0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res."},{"issue":"3","key":"2024121113153681800_CIT0023","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"18","key":"2024121113153681800_CIT0024","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.3390\/jcm11185354","article-title":"Surgical treatment of glioblastoma: state-of-the-art and future trends","volume":"11","author":"Sales","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2024121113153681800_CIT0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/biomedicines12010008","article-title":"Advancements in glioma care: focus on emerging neurosurgical techniques","volume":"12","author":"De Simone","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"2024121113153681800_CIT0026","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"2024121113153681800_CIT0027","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol."},{"issue":"11","key":"2024121113153681800_CIT0028","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2024121113153681800_CIT0029","first-page":"vdae028","article-title":"State of the neoadjuvant therapy for glioblastoma multiforme\u2014Where do we stand","volume":"6","author":"Nabian","year":"2024","journal-title":"Neurooncol. Adv.."},{"issue":"4","key":"2024121113153681800_CIT0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/neuonc\/4.4.261","article-title":"A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy","volume":"4","author":"Gilbert","year":"2002","journal-title":"Neuro-Oncol."},{"issue":"6","key":"2024121113153681800_CIT0031","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/annonc\/mdi183","article-title":"Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide","volume":"16","author":"Brada","year":"2005","journal-title":"Ann Oncol"},{"issue":"12","key":"2024121113153681800_CIT0032","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2006.07.4807","article-title":"Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide","volume":"25","author":"Chinot","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024121113153681800_CIT0033","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/cam4.58","article-title":"Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma","volume":"2","author":"Lou","year":"2013","journal-title":"Cancer Med"},{"issue":"20","key":"2024121113153681800_CIT0034","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.4103\/0366-6999.167313","article-title":"Does early postsurgical temozolomide plus concomitant radiochemotherapy regimen have any benefit in newly-diagnosed glioblastoma patients? A multi-center, randomized, parallel, open-label, Phase II Clinical Trial","volume":"128","author":"Mao","year":"2015","journal-title":"Chin Med J (Engl)."},{"issue":"1","key":"2024121113153681800_CIT0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11060-019-03211-1","article-title":"Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study","volume":"144","author":"Jiang","year":"2019","journal-title":"J Neurooncol."},{"issue":"19","key":"2024121113153681800_CIT0036","doi-asserted-by":"crossref","first-page":"e70291","DOI":"10.1002\/cam4.70291","article-title":"Optimal sequence for total neoadjuvant therapy in locally advanced rectal cancer: an evidence-based review","volume":"13","author":"Ghalehtaki","year":"2024","journal-title":"Cancer Medicine"},{"issue":"12","key":"2024121113153681800_CIT0037","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1080\/0284186X.2017.1332780","article-title":"Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial","volume":"56","author":"Malmstr\u00f6m","year":"2017","journal-title":"Acta Oncol"},{"issue":"12","key":"2024121113153681800_CIT0038","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ejrad.2014.09.018","article-title":"Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis","volume":"83","author":"Zhang","year":"2014","journal-title":"Eur J Radiol."},{"key":"2024121113153681800_CIT0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-016-0702-y","article-title":"Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors","volume":"11","author":"Guo","year":"2016","journal-title":"Radiat Oncol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae195\/60657265\/vdae195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdae195\/61034577\/vdae195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdae195\/61034577\/vdae195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T21:11:14Z","timestamp":1733951474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdae195\/7900016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae195","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"vdae195"}}